This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.

Inclusion Criteria:

• Type 2 Diabetes for more than 12 months, and no previous insulin treatment
• Oral Antidiabetic Drug treatment for at least 4 months
• Body Mass Index (BMI) less than 40 kg/m2
• HbA1c 7.5-10.0%

Exclusion Criteria:

• Current or previous treatment with thiazolidinediones within the last 6 months
• Oral Antidiabetic Drug treatment with combination of three or more Oral Antidiabetic Drugs within the last 6 months
• Proliferative retinopathy or maculopathy
• Known hypoglycaemia unawareness